Previous Article | Next Article 
Journal of Virology, February 2001, p. 1142-1151, Vol. 75, No. 3
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.3.1142-1151.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Function of the Intercistronic Region of
BRLF1-BZLF1 Bicistronic mRNA in Translating the Zta Protein of
Epstein-Barr Virus
Pey-Jium
Chang and
Shih-Tung
Liu*
Molecular Genetics Laboratory, Department of
Microbiology and Immunology, Chang-Gung University, Kwei-Shan,
Taoyuan 333, Taiwan
Received 19 July 2000/Accepted 10 November 2000
 |
ABSTRACT |
Zta, a transcription factor encoded by Epstein-Barr virus, is
efficiently translated from a BRLF1-BZLF1 bicistronic mRNA. In this
study, we demonstrate that inserting a stem-loop structure, which is
known to block ribosome scanning, in the 5' region of the
intercistronic region does not prevent the translation of a luciferase
reporter protein from the bicistronic mRNA fused with the firefly
luciferase gene, suggesting that the translation does not involve
translation reinitiation. Mutational analyses reveal that the region
between nucleotides 86 and 125 (region I) of the intercistronic region
is essential for the translation. Meanwhile, the region between
nucleotides 126 and 165 (region II) is also important since, without
this region, the translation is inefficient. The region I sequence is
partially complementary to the sequence between nucleotides 1489 and
1524 of 18S rRNA. This homology is significant, since disrupting the
homology reduces the translation efficiency. Furthermore, luciferase is
efficiently translated if the entire intercistronic region is replaced
with a sequence complementary to the region between nucleotides 1401 and 1560 of the 18S rRNA. We hypothesize that Rta may assist 40S ribosome in recognizing the region I sequence to start a scanning process for Zta translation.
 |
INTRODUCTION |
Epstein-Barr virus (EBV), a human
herpesvirus, infects lymphoid and epithelial cells. Infection by this
virus is closely related to several neoplastic diseases, including
Burkitt's lymphoma, T-cell lymphoma, Hodgkin's disease, and
nasopharyngeal carcinoma (45). EBV has two distinct life
cycles. After infecting B lymphocytes, the virus immortalizes the cells
and is maintained under latent conditions. During this stage, the virus
expresses six nuclear antigens (EBNAs), three membrane proteins, and
two species of small RNA (EBERs) (31). The viral lytic
cycle is initiated when the cells are exposed to
12-O-tetradecanoylphorbol-13-acetate (TPA), sodium butyrate,
calcium ionophores, or anti-immunoglobulin (6, 14, 35, 51,
55). EBV lytic activation is associated with the expression of
two EBV-encoded immediate-early proteins, Rta and Zta (7, 18,
51). Zta, a transcription factor of the b-Zip family
(15), not only activates the transcription of EBV
immediate-early and early genes (11, 17, 25, 29, 49) but
also binds to the lytic origin of EBV, which is a prerequisite for EBV
lytic replication (16, 48). Rta protein is another transcription factor, often acting synergistically with Zta to activate
EBV lytic genes (11, 25, 30).
Rta and Zta are encoded by BRLF1 and BZLF1, respectively. These two
genes are situated adjacent to each other on the EBV genome (5). During the immediate-early stage of the EBV lytic
cycle, a 1.0-kb monocistronic BZLF1 mRNA is transcribed from a promoter (PZ) located immediately upstream from the gene (Fig.
1A) (37). BZLF1 is also
transcribed from the promoter of BRLF1 (PR)
(37). The mRNA transcribed from this promoter is 4 kb
long. This mRNA is spliced into a 3.3-kb mRNA or an 0.8-kb mRNA (Fig.
1A) (37). The 0.8-kb transcript (Fig. 1A) encodes an
Rta-Zta fusion protein called RAZ. This protein forms a heterodimer
with Zta to inhibit the function of Zta (19). The 3.3-kb
transcript is bicistronic, containing both BRLF1 and BZLF1 (Fig. 1A)
(37). In an early study, we used a plasmid containing a
BRLF1-ZLUC bicistronic transcription unit transcribed from the
cytomegalovirus immediate-early promoter (PC) and
demonstrated that only the bicistronic mRNA is transcribed from the
plasmid in P3HR1 cells and EBV-negative Akata cells; the PZ
promoter remains inactive, and the monocistronic ZLUC mRNA is not
transcribed in the cells (9). That study also demonstrated that both Rta and Zta are efficiently translated from the bicistronic mRNA. Furthermore, the bicistronic transcript is not further spliced or
cleaved, indicating that the Zta protein is not translated from a
degradation product of the 3.3-kb mRNA (9). Genetic studies also demonstrated that deletion, insertion, frameshift, and
nonsense mutations in BRLF1 abolish the translation of Zta from the
bicistronic mRNA. Additionally, these mutations can be complemented by
a functional BRLF1, indicating that Rta protein is required for
translating Zta from the bicistronic mRNA (9).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
(A) mRNAs transcribed from PR and
PZ during the EBV lytic cycle. The pre-mRNA transcribed
from PR (4.0 kb) is spliced into a 3.3-kb and an 0.8-kb
mRNA. An inhibitor of Zta called RAZ is translated from the 0.8-kb
transcript. Meanwhile, the 1.0-kb BZLF1 transcript is transcribed from
PZ. The black and white boxes represent the exons of BZLF1
and BRLF1, respectively. (B) The intercistronic region of the
BRLF1-BZLF1 bicistronic mRNA is 210 nucleotides long. The region
includes five ORFs. The initiation codons of these ORFs are boxed and
numbered. This area also contains two large inverted repeats, SI and
SII. Regions I and II are the two crucial regions for Zta translation
from the bicistronic mRNA. Meanwhile, KspI and
HindIII are the restriction enzyme sites created by
site-directed mutagenesis. TATA, TATA sequence of PZ; +1,
transcription start site of BZLF1 monocistronic mRNA. (C) Plasmids
pCMV-RZLUC(KspI) and pCMV-R-LUC are the reporter plasmids used for the
analysis of bicistronic translation.
|
|
In eukaryotic cells, mRNAs are rarely bicistronic. However, if an mRNA
contains two open reading frames (ORFs), the presence of the upstream
ORF (uORF) often regulates the translation of the downstream ORF,
leading to a scenario in which the downstream ORF is either poorly
translated or not translated (34). This phenomenon is
explained by translation typically being initiated from the cap site of
mRNA, subsequently leading to translation of uORF. However, after
translating the uORF, ribosomes may lose all the initiation factors
associated with 40S ribosome and be unable to continue to scan the
intercistronic region to initiate translation of the downstream ORF
(33). According to a translation reinitiation model, if a
bicistronic mRNA includes a short uORF, ribosomes which translated uORF
may still retain some initiation factors following translation
(36). Such a retaining effect may allow 40S ribosome to
scan the intercistronic region to begin translation of the downstream
ORF (34). For example, efficiency of translation
reinitiation in human immunodeficiency virus type 1 mRNA is determined
by the length of uORF and by intercistronic distance (36).
Another example of translation reinitiation is the translation of GCN4
of Saccharomyces cerevisiae, which acts as a transcription
activator of amino acid biosynthesis genes (28). The
GCN4 ORF in mRNA is preceded by four short uORFs (uORF1 to
uORF4). As is generally known, translation of GCN4 first involves translation of uORF1. Meanwhile, after uORF1 is translated, 40S ribosome continues to scan the sequence downstream. Under nonstarvation conditions, the translation initiation complex is reassembled rapidly,
allowing translation to reinitiate from the initiation codon of uORF4.
This translation apparently inhibits the translation of GCN4. However,
under starvation conditions, a greater scanning distance is required
for 40S ribosome to recruit the translation initiation factors
necessary to form a translation initiation complex. Such a requirement
explains why 40S ribosome neglects the initiation codon of uORF4 and
initiates translation from the initiation codon of GCN4
(1, 39). Besides the translation reinitiation mechanism,
translation of a bicistronic mRNA can also involve a mechanism called
leaky scanning (10, 34). If the AUG codon of a uORF is
surrounded by a reading context that does not favor translation
initiation, 40S ribosome may skip this AUG codon and use a downstream
AUG codon for translation initiation. In addition to ribosome scanning
and leaky scanning, the genomes of certain viruses are translated by
directly attaching ribosome subunits to an internal ribosome entry site
(IRES) in the 5' untranslated region (internal initiation)
(41). Several types of IRESs have been defined, which
differ in sequence and structure (42, 53). Meanwhile,
eIF-4B and several other proteins binding to the polypyrimidine tract
in the IRES are involved in internal initiation (43). In
addition to internal initiation, translation of viral protein may
occasionally involve ribosome shunting (22, 23, 54). In
the case of cauliflower mosaic virus 35S RNA, shunting allows ribosomes
to bypass the elements which block ribosome scanning in the
untranslated region (20, 22) and requires the activity of
a virus-encoded translational transactivator (21). In this study, we demonstrate that Zta protein is translated from the BRLF1-BZLF1 bicistronic mRNA by a discontinuous ribosome-scanning mechanism similar to ribosome shunting or internal initiation. In
addition, a sequence that complements helix 36 of 18S rRNA in the
intercistronic region is required for initiating the translation.
 |
MATERIALS AND METHODS |
Cell line.
An EBV-positive Burkitt's lymphoma cell line,
P3HR1, was used for transfection studies. Cells were cultured in RPMI
1640 medium supplemented with 10% fetal calf serum.
Plasmids.
Plasmids pGL2-Basic and pGEM-7Zf(
) were
purchased from Promega Corp. (Madison, Wis.). Plasmid pCMV-RZLUC
(9) contains a BRLF1-BZLF1 transcription unit transcribed
from PC, in which BZLF1 is fused with the firefly
luciferase gene (luc). Plasmid pCMV-RZLUC(KspI), a
derivative of pCMV-RZLUC (9), contained a newly created
KspI site located 5 nucleotides downstream from the
termination codon of BRLF1. This KspI site was created by the method of Ho et al. (24), using PCR primers KSPA
(5'-ATTTTAGACACCGCGGAAAACTGCC) and 3-ATG
(5'-CTATGAGGTATATTAGCAATGCC) and primers KSPB
(5'-GGCAGTTTTCCGCGGTGTCTAAAAT) and RZR
(5'-GATGAATGTCTGCTGCATGCCATGC). PCR was performed, using pCMV-RZLUC as a template under conditions of 94°C for 30 s,
56°C for 60 s, and 72°C for 60 s, for 35 cycles.
Approximately 1/10 of the PCR fragments was mixed and reamplified
without adding any primers under conditions of 94°C for 30 s,
45°C for 60 s, and 72°C for 60 s, for 25 cycles. The PCR
fragment was further amplified with primers RZR and 3-ATG. The
amplified fragment was cut with NsiI and was used
to replace the NsiI fragment in pCMV-RZLUC to
generate pCMV-RZLUC(KspI). Plasmids pRZLUC(XBA) and pCMV-RZLUC(XBA) were generated by adopting a similar strategy. Plasmid
pCMV-RZLUC(KSP-SL) was generated by inserting a double-stranded
oligonucleotide, SL-A
(5'-CCGCGGCGCGTGGTGGCGGCTGCAGCCGCCACCACGCGCGGCGG) into the KspI site of pCMV-RZLUC(KspI). Plasmid
pCMV-RZLUC(STY-SL) was generated by inserting a double-stranded
oligonucleotide, SL-B (5'-GAATTCCCATCTTGGGAATTC), into the
StyI site of pCMV-RZLUC(KspI). Plasmid pGEM-SS was
constructed by inserting the SphI fragment of pCMV-RZLUC,
which contained the 3' region of BRLF1, the intercistronic region, and
the 5' region of ZLUC, into the SphI site of pGEM-7Zf(
). Plasmid pGEM-SS(KspI) was identical to pGEM-SS except that the SphI fragment from pCMV-RZLUC(KspI) was inserted. Plasmid
pGEM-SS(DZ) was identical to pGEM-SS(KspI) except that the BZLF1
sequence in ZLUC was deleted and a HindIII site was
present at the 3' terminus of the intercistronic region. Plasmid
pCMV-R-LUC was constructed by replacing the SphI fragment of
pCMV-RZLUC(KspI) with the SphI fragment of pGEM-SS(DZ).
Plasmid pCMV-R-LUC(BC) is a derivative of pCMV-R-LUC in which the
intercistronic region (the KspI-HindIII fragment) was replaced by a 133-nucleotide sequence (nucleotide 8628 to
nucleotide 8760 of the EBV genome) amplified from the BamHI-C fragment of EBV. The forward primer for amplifying
this 133-nucleotide fragment contained a KspI site at the 5'
end; the reverse primer contained a HindIII site at the
5' end. The amplified DNA fragment was digested by KspI and
HindIII and was used to replace the
KspI-HindIII fragment of pGEM-SS(KspI) to
generate pGEM-SS(BC). The SphI fragment of this plasmid was
then isolated by restriction digestion and was used to replace the
SphI fragment of pCMV-RZLUC to generate pCMV-R-LUC(BC).
Next, a double-stranded oligonucleotide, consisting of the sequence
from nucleotides 86 to 125 of the intercistronic region (region I), was
inserted into the SpeI site, which is located at the 40th
nucleotide of the 133-nucleotide BamHI-C fragment in
pGEM-SS(BC). The fragment was then isolated by SphI
digestion and was used to replace the SphI fragment of
pCMV-RZLUC to generate pCMV-R-LUC(BC-RI). Plasmid pCMV-R-LUC(BC-RII)
was constructed with a similar method with a double-stranded
oligonucleotide consisting of the region II sequence (from nucleotides
126 to 165 of the intercistronic region). Plasmids pRZLUC(D33) and
pCMV-RZLUC(D33) were generated by amplifying a fragment lacking the
33-bp region downstream from the StyI site of the
intercistronic region. The forward primer used for amplification contained an StyI site at the 5' end. The amplified fragment
was digested with StyI and HindIII and was
used to replace the StyI-HindIII fragment in
pGEM-SS. The fragment was reisolated from pGEM-SS by SphI
digestion to replace the SphI fragment in pRZLUC and
pCMV-RZLUC. Plasmids pRZLUC(D62) and pCMV-RZLUC(D62) were generated by
similar methods. Mutants 5'-45, 5'-85, 5'-165, and 5'-205 contained a deletion from the KspI site to the 45th, 85th, 165th, and
205th nucleotides in the intercistronic region, respectively. Deletion 5'-45 was generated by amplifying a fragment containing the region between nucleotide 45 of the intercistronic region and the 15th nucleotide of BZLF1, using pGEM-SS(KspI) as a template. The forward primer used for amplification contained a KspI site at the
5' end. The amplified fragment was cut by KspI and
StyI and was then used to replace the
KspI-StyI fragment of pGEM-SS(DZ). The
SphI fragment of this plasmid was isolated by restriction
digestion and was used to replace the SphI fragment in
pCMV-R-LUC to generate a plasmid containing the 5'-45 deletion.
Mutation 5'-85 was generated by a similar strategy. Mutation 5'-165 was
generated by digesting pGEM-SS(KspI) with NotI and
XhoI, treating the fragment with T4 DNA polymerase, and
ligating with T4 DNA ligase. This procedure removed the
NotI-XhoI fragment as well as the XbaI
site on the vector portion of the plasmid. This plasmid,
pSS-KspI(
XbaI), was used as a template to amplify a DNA fragment
containing the region from nucleotide 165 of the intercistronic region
to the 5' region of luc. The forward primer used for PCR
contained a KspI site at the 5' end. The PCR fragment was
digested with KspI and XbaI; the fragment was
used to replace the KspI-XbaI fragment in
pSS-KspI(
XbaI). The resulting plasmid was cut with SphI,
and the restriction fragment was used to replace the SphI
fragment in pCMV-RZLUC. Deletion 5'-128 was generated by first deleting the KspI-StyI fragment of pGEM-SS(DZ). Next, the
SphI fragment of the resulting plasmid was isolated and used
to replace the SphI fragment in pCMV-RZLUC. Deletion 5'-205
was generated with a method similar to that used for generating the
5'-128 deletion. Deletion 3'-86 was generated by amplifying a DNA
fragment covering the region between the last 7 nucleotides of BRLF1
and the 85th nucleotide of the intercistronic region, using
pCMV-RZLUC(KspI) as a template. The primers used for amplification were
D1 (5'-ATTTTAGACACCGCGGAAAACTGCC) and D2
(5'-CAAGCTTTTTAGGTGTGTCTATGAGGT). In primer D2, a
HindIII site was present at the 5' end. The PCR fragment
was digested with KspI and HindIII; the
fragment was used to replace the KspI-HindIII fragment of pCMV-R-LUC. Deletion 3'-166 was generated by the same method except that primer D3 (5'-GAAGCTTTGAGTTACCTGTCTAACATC) instead of D2 was used. Deletion 3'-129 was generated by cutting pGEM-SS(DZ) with StyI and HindIII. The
plasmid was then self-ligated after the DNA was repaired with the
Klenow fragment of DNA polymerase I. The SphI fragment was
then isolated and was used to replace the SphI fragment in
pCMV-R-LUC. Mutant R86-165 was generated by cutting a pGEM-SS(DZ)
derivative, containing the 5'-85 deletion, with MluI and
StyI. The fragment was isolated and was used to replace the
MluI-StyI fragment of the 3'-166 deletion mutant
of pGEM-SS(DZ). The SphI fragment was then isolated to
replace the SphI fragment in pCMV-RZLUC. 18SC and 18S
fragments, containing the region between nucleotide 1401 and nucleotide
1560 of 18S rRNA, were amplified, using the DNA of P3HR1 cells as a
template. In the 18SC fragment, a KspI site was created at
the end with nucleotide 1560 and a HindIII site was
created at the other end. This DNA was used to replace the
KspI-HindIII fragment of pGEM-SS(KspI). The
fragment was isolated by SphI digestion and was used to
replace the SphI fragment in pCMV-RZLUC to generate
pCMV-R-LUC(18SC). Plasmid pCMV-R-LUC(18S) was generated by the same
method except that the KspI and the HindIII
sites were created at the opposite ends of the 18S DNA fragment. The
constructs described herein were also generated in pRZLUC and pR-LUC,
which have sequences identical to those of pCMV-RZLUC and pCMV-R-LUC,
except without PC. Plasmid pBMLF1-luc contains a BMLF1
promoter (nucleotides 84850 to 84289 of the EBV genome) inserted into
the SmaI site upstream from a luc gene in
pGEM-7Zf(
). Moreover, linker-scanning mutants were generated by
site-directed mutagenesis (24). In each linker-scanning
mutant, every nucleotide A was changed to nucleotide C and vice versa,
and every nucleotide G was changed to nucleotide T and vice versa. The
five initiation codons in the intercistronic region were changed to
GTG, TTG, ATA, TTG, and GTG, respectively, by site-directed mutagenesis
(24).
Northern blot analysis.
Total RNA was isolated from P3HR1
cells with guanidinium isothiocyanate and was purified by CsCl
centrifugation according to a method described elsewhere
(46). RNA was separated by electrophoresis on a 1%
agarose-formaldehyde gel and was transferred to a nylon membrane
(Amersham). A glyceraldehyde-3-phosphate dehydrogenase probe
(8) and a luc probe (9) were
prepared by in vitro transcription with T7 RNA polymerase.
Hybridization was performed according to a method described elsewhere
(9).
Transfection and luciferase assay.
Plasmids used for the
transfection studies were prepared by CsCl gradient centrifugation
according to a method described elsewhere (46). For
plasmid transfection, 10 µg of plasmid DNA was mixed with 5 × 106 cells in 300 µl of culture medium. Electroporation
was performed at 960 µF and 0.2 kV with a Bio-Rad (Richmond, Calif.)
Gene Pulser electroporator. After electroporation, cells were
transferred to 10 ml of fresh culture medium. TPA at a final
concentration of 30 ng/ml and sodium butyrate at a final concentration
of 3 mM were added to induce the EBV lytic cycle. Cell lysate was
prepared 24 h after transfection according to a method previously
described (13). Each transfection experiment was repeated
at least three times, and each sample in the experiment was prepared in duplicate.
DNA sequencing.
DNA sequencing was performed according to
the chain termination method of Sanger et al. (47). The
constructs reported herein were confirmed by sequencing.
 |
RESULTS |
Intercistronic region and bicistronic translation.
Plasmid
pCMV-RZLUC was constructed by cloning the BRLF1-BZLF1 transcription
unit downstream from PC and fusing the 5' 75 nucleotides of
BZLF1 with the firefly luciferase gene (luc). In an earlier study, we confirmed that a BRLF1-ZLUC bicistronic mRNA is transcribed from this plasmid and a Zta-Luc (Zluc) fusion protein is efficiently translated from the bicistronic mRNA (9). Because
pCMV-RZLUC does not contain a convenient restriction enzyme site that
would allow mutations to be generated in the intercistronic region, we
created a KspI site located 5 nucleotides downstream from
the termination codon of BRLF1 in pCMV-RZLUC (Fig. 1B). The plasmid containing this site, pCMV-RZLUC(KspI) (Fig. 1C), exhibited a luciferase activity about equal to that displayed by pCMV-RZLUC (Fig.
2), indicating that the sequence change
does not influence the translation of Zluc. The BZLF1 sequence in
pCMV-RZLUC(KspI) was then removed to generate pCMV-R-LUC (Fig. 1B and
C). This deletion increased luciferase activity by 1.2-fold (Fig. 2).
Despite the sequence of BZLF1 being deleted in pCMV-R-LUC, the
initiation codon of luc remains and has a more favorable
reading context than the initiation codon of BZLF1, explaining the
increased activity. The intercistronic region in pCMV-R-LUC was then
deleted by KspI-HindIII digestion. This
deletion reduced the expression by approximately 90% (Fig. 2, D-KH).
The intercistronic region (KspI-HindIII
fragment) in pCMV-R-LUC was also replaced with a 133-bp fragment
isolated from the BamHI-C fragment of EBV. This replacement
did not lead to the translation of luciferase (Fig. 2, BC), indicating
that the intercistronic region is crucial for translating Zta.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 2.
Requirement of the intercistronic region for the
bicistronic translation. Plasmids pCMV-RZLUC (RZLUC),
pCMV-RZLUC(KspI) [RZLUC(KspI)], pCMV-R-LUC (R-LUC),
pCMV-R-LUC(D-KH) (D-KH), and pCMV-R-LUC(BC) (BC) were transfected into
P3HR1 cells. The luciferase activity exhibited by these plasmids was
monitored at 24 h after transfection.
|
|
Mutation of the TATA sequence of the BZLF1 promoter.
The TATA
sequence of the BZLF1 promoter was also mutated (Fig.
3A) to examine how the mutation affects
the expression of luciferase reporter protein. As expected, luciferase
was not expressed from pRZLUC in P3HR1 cells under latent conditions
(Fig. 3B) owing to the lack of transcription of BRLF1-ZLUC bicistronic
mRNA and luc monocistronic mRNA. On the other hand,
luciferase was expressed at a high level if the cells were treated with
TPA and sodium butyrate (Fig. 3B), indicating that this treatment
activates the BZLF1 promoter. This activation was not observed,
however, if the TATA sequence was changed from TTTAAA to
TCTAGA (an XbaI sequence) (Fig. 3B, XBA),
indicating that the mutation severely inhibits the ability of the
plasmid to transcribe the monocistronic mRNA under lytic conditions.
The same mutation in pCMV-RZLUC decreased the expression of luciferase
only 22% under latent conditions (Fig. 3C). Since Rta is known to
activate PZ (2, 44), a cotransfection study
was performed to examine whether Rta activates the transcription of
ZLUC monocistronic mRNA from the XBA construct. According to our
results, cotransfecting pCMV-R and a reporter plasmid containing a
luc gene transcribed from the BMLF1 promoter resulted in a
high-level expression of luciferase activity (Fig. 3D), indicating that
the Rta protein expressed from pCMV-R is capable of activating an EBV
early promoter. On the other hand, Rta protein expressed from pCMV-R
did not activate the transcription from the XBA mutant construct
lacking a PC (Fig. 3D), indicating that Rta protein is
incapable of activating the mutant Zp promoter. In addition, under our
experimental conditions, Rta does not activate the Zp in pRZLUC (Fig.
3D). The TATA sequence was also removed by deletion. Deleting 33 and 62 nucleotides from the StyI site abolished the expression of
luciferase from pRZLUC under lytic conditions (Fig. 3B). On the other
hand, the deletions in pCMV-RZLUC decreased the expression by only 25 and 35%, respectively (Fig. 3C), demonstrating that expression of
luciferase by the TATA mutants of pCMV-RZLUC is unrelated to the
transcription of ZLUC monocistronic mRNA.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 3.
Effects of TATA mutations and expression of Zluc
reporter protein. (A) The TATA sequence (TTTAAA) of the BZLF1 sequence
was either changed to TCTAGA (XbaI sequence) by
site-directed mutagenesis or removed by deletion (D33, D62, and D-KH).
(B) Plasmid pRZLUC (wild type) and its mutant derivatives (XBA, D33,
D62, and D-KH) were transfected into P3HR1 cells. After transfection,
cells were maintained under latent conditions (black bars) or treated
with TPA and sodium butyrate (white bars) to induce the viral lytic
cycle. (C) Plasmids pCMV-RZLUC (wild type) (white bars) and pRZLUC
(wild type) (black bars) and their respective mutant derivatives (XBA,
D33, D62, and D-KH) were transfected into P3HR1 cells, which were
maintained under latent conditions. (D) Effects of Rta on the
expression of luciferase from pCMV-RZLUC, the promoter of BMLF1
(pBMLF1-luc), the XBA mutant, pRZLUC, and pGL2-Basic. Luciferase
activity was monitored at 24 h after transfection. ZIB, ZIC,
ZIIIA, ZIIIB, ZII, and TATA sequences are cis elements
regulating the transcription of BZLF1. S, StyI site; X,
XbaI site; H, HindIII site.
|
|
ORFs in the intercistronic region and the translation of Zta.
The intercistronic region of BRLF1-BZLF1 bicistronic mRNA contains five
ORFs (Fig. 1B). To examine whether Zta protein is translated from the
bicistronic mRNA by a translation reinitiation mechanism, we altered
the initiation codon of these ORFs in pCMV-RZLUC to GUG, UUG, AUA, UUG,
and GUG, respectively, to investigate whether these changes influence
the translation. Theoretically, these sequence changes should remove
the potential suppressive uORFs and increase the translation efficiency
of the downstream ORF if Zluc translation indeed involves translation
reinitiation. According to our results, altering the first, second,
third, and fifth AUG codons did not significantly influence the
translation of Zluc (Fig. 4). Meanwhile,
altering the sequence of the fourth AUG codon reduced luciferase
activity by roughly 40% (Fig. 4).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
Mutations of the AUG sequences in the intercistronic
region and Zluc translation. The five AUG sequences in pCMV-RZLUC were
altered to GUG (1st), UUG (2nd), AUA (3rd), UUG (4th), and GUG (5th),
respectively. The plasmids were transfected into P3HR1 cells, and
luciferase activity was monitored at 24 h after transfection.
|
|
Effect of high-energy stem-loop structures in the intercistronic
region.
A 44-nucleotide sequence, SL-A, was inserted into the
KspI site of pCMV-RZLUC(KspI) (Fig. 1B) to elucidate how
Zluc fusion protein is translated from the bicistronic mRNA. Kozak
(32) demonstrated that the SL-A sequence, when transcribed
into RNA, forms a hairpin structure with a
G value of
64 kcal/mol, which can effectively block ribosome scanning. Inserting
this sequence at the KspI site not only failed to prevent
Zluc translation but also increased Zluc expression 1.8-fold (KSP-SL
[Fig. 5]), suggesting that the
ribosomes that translated Rta do not continue to scan the
intercistronic region. Our results also show that inserting the SL-A
sequence did not influence the transcription of the bicistronic mRNA
(see lanes c to e, Fig. 9). We also inserted a stem-loop structure,
SL-B, into the StyI site in the intercistronic region (Fig.
1B). SL-B has a
G value of
14 kcal/mol, although it has an energy level lower than that of SL-A, and has also been demonstrated elsewhere to block ribosome scanning (1). Unlike the SL-A
insertion, this insertion lowered Zluc translation to the background
level (Fig. 5, STY-SL). The SL-A sequence was also inserted into the KspI site of pRZLUC(KspI), a plasmid that does not contain
PC and is incapable of transcribing the bicistronic mRNA.
This insertion did not lead to the expression of luciferase (data not
shown). Finally, we inserted the SL-A sequence into the KspI
site of two mutant derivatives of pCMV-RZLUC(KspI), APA-FS and
BA,
which contain a mutation in BRLF1 and cannot translate Zluc
(9). Inserting the SL-A sequence into the KspI
site of these mutant constructs did not result in Zluc translation
(Fig. 5, APA-KSL and
BA-KSL).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 5.
Insertion of high-energy stem-loop structures into the
intercistronic region and the translation of Zluc. SL-A and SL-B are
two stem-loop structures known to block ribosome scanning. KSP,
pCMV-RZLUC(KspI); KSP-SL, SL-A sequence inserted into the
KspI site of pCMV-RZLUC(KspI); APA-KSL, the SL-A sequence
inserted into the KspI site of a mutant derivative of
pCMV-RZLUC(KspI), containing a frameshift mutation at the
ApaI site in BRLF1; BA-KSL, SL-A sequence inserted into
the KspI site of a mutant derivative of pCMV-RZLUC(KspI),
containing a BstXI-ApaI deletion in BRLF1;
STY-SL, SL-B sequence inserted into the StyI site in the
intercistronic region of pCMV-RZLUC(KspI).
|
|
Deletion analysis of the intercistronic region.
Deletions were
generated to delineate the sequence in the intercistronic region
essential for translation. Deleting the region from the
KspI site to nucleotide 45 (5'-45) and nucleotide 85 (5'-85) of pCMV-R-LUC (Fig. 6A) did not
influence the translation of luciferase (Fig. 6B). However, deletion
from the KspI site to nucleotide 128 (the StyI
site) (5'-128), nucleotide 165 (5'-165), and nucleotide 205 (5'-205) reduced luciferase activity by approximately 80 to 90% (Fig.
6B). Also examined was the effect of the 3' deletions on the
translation of luciferase. Deletion from the HindIII
site to nucleotide 166 (3'-166) (Fig. 6A) did not influence luciferase translation. Furthermore, deletions to nucleotide 129 (3'-129) and 86 (3'-86) (Fig. 6A) decreased luciferase activity by approximately 80 to
85% (Fig. 6B). Deleting both the regions upstream from nucleotide 85 and downstream from nucleotide 166 did not influence the translation (Fig. 6B, R86-165). These results suggested that the region between nucleotides 86 and 165 is critical for translating the downstream ORF.
Northern blot analysis also revealed that these deletions did not
significantly influence the transcription of the bicistronic mRNA (see
lanes p to w, Fig. 9).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 6.
Deletion analysis of the intercistronic region. (A)
Deletions were generated from the KspI site of pCMV-R-LUC to
nucleotides 45 (5'-45), 85 (5'-85), 128 (5'-128), 165 (5'-165), and 205 (5'-205). Deletions were also generated from the HindIII
site to nucleotides 166 (3'-166), 129 (3'-129), and 86 (3'-86). In
R86-165, the regions upstream from nucleotide 85 and downstream
from nucleotide 166 were deleted. (B) The plasmids were transfected
into P3HR1 cells, and luciferase activity exhibited by the plasmids was
examined at 24 h after transfection.
|
|
Linker-scanning analysis.
The importance of the region between
nucleotides 86 and 165 in pCMV-R-LUC(R86-165) was further studied
through linker-scanning analysis. A mutation in the region between
nucleotides 86 and 95 (M86-95) decreased luciferase activity by
approximately 51% (Fig. 7), a mutation
between nucleotides 96 and 105 (M96-105) decreased the activity by
54%, a mutation between nucleotides 106 and 115 (M106-115) decreased
the activity by 70% (Fig. 7), and a mutation between nucleotides 136 and 145 (M136-145) decreased luciferase activity by 77% (Fig. 7).
Changing the sequence between nucleotides 116 and 135 (M116-125 and
M126-135) decreased expression by 30 to 40% (Fig. 7). Mutations in the
region between nucleotides 146 and 165 (M146-155 and M156-165) only
slightly decreased luciferase expression (Fig. 7). A Northern blot
analysis revealed that these mutations did not significantly influence
the transcription of bicistronic mRNA (see lanes f to m, Fig. 9).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 7.
Linker-scanning analysis. The intercistronic region was
replaced by an RNA comprising the sequence between nucleotides 86 and
165 in the intercistronic region (R86-165). Mutations were generated in
the regions in the plasmid between nucleotides 86 and 95 (M86-95), 96 and 105 (M96-105), 106 and 115 (M106-115), 116 and 125 (M116-125), 126 and 135 (M126-135), 136 and 145 (M136-145), 146 and 155 (M146-155), and
156 and 165 (M156-165). The plasmids were transfected into P3HR1 cells,
and luciferase activity exhibited by the plasmids was examined at
24 h after transfection.
|
|
Involvement of a sequence complementary to the 18S rRNA in Zta
translation.
The sequence between nucleotides 86 and 165 is
arbitrarily divided into two regions
region I and region II. Region I,
from nucleotides 86 to 125, is partially complementary to the region between nucleotides 1484 and 1528 of 18S rRNA (Fig.
8A and B). This study has already
demonstrated that luciferase protein is not translated from the
bicistronic mRNA transcribed from pCMV-R-LUC(BC), where the
intercistronic region is replaced with a 133-bp sequence from the
BamHI-C fragment of EBV (Fig. 2). Inserting the region I
sequence into the intercistronic region in pCMV-R-LUC(BC) partially restored the translation of luciferase to a level approximately 50% of
that exhibited by the wild-type construct (Fig. 8C, BC-RI). Meanwhile,
inserting the region II sequence into the intercistronic region in
pCMV-R-LUC(BC) did not result in the translation of luciferase (Fig.
8C, BC-RII). We also substituted the entire intercistronic region with
a fragment containing the sequence between nucleotide 1401 and
nucleotide 1560 of 18S rRNA. If the sequence was inserted in an
orientation complementary to 18S rRNA, the plasmid [pCMV-R-LUC(18SC)] exhibited luciferase activity equivalent to that exhibited by the
wild-type construct (Fig. 8C). Luciferase was not translated, however,
if the 18S sequence was inserted in the opposite orientation (Fig. 8C,
18S). Hybridization analysis also revealed that a lack of translation
by the 18S mutant is not attributed to a lack of transcription of the
bicistronic mRNA (see lanes n and o, Fig. 9). Inserting SL-A into the
KspI site of pCMV-R-LUC(18SC) did not affect the
translation. Meanwhile, inserting the SL-A sequence into the APA-FS
frameshift mutation in pCMV-R-LUC(18SC) did not lead to the translation
of the reporter protein (Fig. 8C).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 8.
Sequence complementation between region I (nucleotides
86 to 125 in the intercistronic region) and the region between
nucleotides 1484 and 1528 of 18S rRNA (A), the sequence and the
structure of helix 36 of 18S rRNA (B), and the importance of the region
I sequence in translating luciferase protein from the bicistronic mRNA
(C). The intercistronic region in pCMV-R-LUC (R-LUC) was replaced with
a 133-nucleotide sequence from the BamHI-C fragment of EBV
(BC). The sequences between nucleotides 86 and 125 (BC-RI) and between
nucleotides 126 and 165 (BC-RII) of the intercistronic region were
inserted into the SpeI site of the BamHI-C
fragment. The intercistronic region was also replaced with a fragment,
consisting of the sequence between nucleotides 1401 and 1560 of 18S
rRNA. The sequence was inserted in an orientation that complements the
18S rRNA (18SC) or in the opposite orientation (18S). The nucleotides
complementary to those in region I are indicated by dots in panel B. 18SC(SL-A), SL-A sequence inserted into the KspI site in
pCMV-R-LUC(18SC); 18SC(APA-FS), pCMV-R-LUC(18SC) containing a
frameshift mutation at the ApaI site in BRLF1; h33 to h44,
helices in 18S rRNA; numbers, nucleotide positions.
|
|
 |
DISCUSSION |
Zluc is translated from the BRLF1-ZLUC bicistronic mRNA.
As is
generally known, EBV in P3HR1 cells can occasionally enter a lytic
cycle spontaneously. This lytic activation is presumably attributed to
the transcription of monocistronic BZLF1 mRNA. Therefore, in our
experiments, we used freshly cultured cells for transfection and for
Northern blot analysis and RNA was isolated within 15 to 20 h
after transfection. Ragoczy et al. (44) and Adamson et al.
(2) recently demonstrated that Rta protein, when expressed at extremely high levels, activates the transcription of BZLF1 monocistronic mRNA. This raises the possibility that Rta protein translated from the BRLF1-ZLUC bicistronic mRNA might have activated the transcription of ZLUC monocistronic mRNA that was undetected by
Northern blot analysis and resulted in the expression of Zluc. To
eliminate these possibilities, we mutated the TATA sequence of the
BZLF1 promoter to examine the consequence of the mutations for Zluc
expression. Our study reveals that the BZLF1 promoter in the pRZLUC
construct is functional in P3HR1 cells, since Zluc was expressed at a
high level when the cells were treated with TPA and sodium butyrate
(Fig. 3B). Varying or deleting the TATA sequence in pRZLUC apparently
destroys the function of the promoter, since Zluc is not expressed
after lytic induction by TPA and sodium butyrate (Fig. 3B). In the case
of pCMV-RZLUC, the TATA mutations in the plasmid do not significantly
influence the expression of Zluc under latent conditions (Fig. 3C),
demonstrating that Zluc expression is independent of the transcription
of ZLUC monocistronic mRNA. The most important evidence, in which
transcription of monocistronic ZLUC mRNA is demonstrated to be
unimportant, likely comes from the 18SC construct (Fig. 8). In this
plasmid, the entire intercistronic region, which comprises the most
important region of PZ, is replaced by the helix 36 sequence of the 18S rRNA. Although completely destroying the function
of PZ, this replacement does not influence the expression
of Zluc, demonstrating that Zluc is indeed translated from the
bicistronic mRNA. Notably, our study reveals that the M106-115 and the
M136-145 linker-scanning mutations in pCMV-RZLUC significantly lower
the expression of Zluc (Fig. 7). These two mutations alter the ZII and
the TATA sequences of PZ (Fig. 3A). Although these two
regions are important for activation of the BZLF1 promoter by Rta
(2) and for transcription of ZLUC monocistronic mRNA,
respectively, the activity decreases are probably unrelated to the
transcriptional functions of these cis elements. In this study, we have performed a Northern blot analysis and demonstrated that
the mutations that we have generated do not significantly influence the
transcription of the bicistronic mRNA in P3HR1 cells (Fig.
9).

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 9.
Transcription of bicistronic mRNA from the plasmids
containing mutations in the intercistronic region. RNA was purified
from P3HR1 cells transfected with bicistronic and monocistronic markers
(lane a), pRZLUC (lane b), pCMV-RZLUC (lane c), pCMV-RZLUC(SL-A) (lane
d), pCMV-RZLUC(Ksp) (lane e), pCMV-RZLUC(M86-95) (lane f),
pCMV-RZLUC(M96-105) (lane g), pCMV-RZLUC(M106-115) (lane h),
pCMV-RZLUC(M116-125) (lane i), pCMV-RZLUC(M126-135) (lane j),
pCMV-RZLUC(M136-145) (lane k), pCMV-RZLUC(M146-155) (lane l),
pCMV-RZLUC(M156-165) (lane m), pCMV-RZLUC(18S) (lane n),
pCMV-RZLUC(18SC) (lane o), 5'-45 deletion (lane p), 5'-85 deletion
(lane q), 5'-128 deletion (lane r), 5'-165 deletion (lane s), 5'-205
deletion (lane t), 3'-166 deletion (lane u), 3'-129 deletion (lane v),
and 3'-86 deletion (lane w). A 32P-labeled luc
probe was used for hybridization. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
|
|
Translation of Zluc from the bicistronic mRNA involves a
discontinuous ribosome-scanning process.
As is generally known,
uORFs typically decrease the efficiency of the translation of the
downstream major ORF (20). Therefore, if Zluc is
translated by translation reinitiation, uORFs in the intercistronic
region should lower the efficiency of ZLUC translation. This inhibitory
effect can be demonstrated by altering the AUG codons to remove the
uORFs. This accounts for why we changed the five initiation codons in
the intercistronic region. According to our results, the ORFs in the
intercistronic region are unimportant for the bicistronic translation
since altering the initiation codon of these ORFs does not affect the
translation, except for the mutation in the fourth initiation codon,
which decreases luciferase activity by approximately 40% (Fig. 4).
This decrease is probably attributable to the disruption of the
homology between region I and 18S rRNA (Fig. 8A) rather than to the ORF
itself playing a role in the translation. Furthermore, we inserted a
hairpin structure, SL-A, known to block ribosome scanning, into the 5' region of pCMV-RZLUC(KspI). This insertion apparently does not hinder
Zluc translation (Fig. 5), suggesting that the ribosome that translated
Rta does not continue to scan the 5' region of the intercistronic
region and that Zta translation does not involve translation
reinitiation. Notably, the SL-A insertion actually increases Zluc
translation by 1.8-fold (Fig. 5). The reason for this increase remains
unknown. Possibly, SL-A may have changed the conformation of the
intercistronic region, thus causing the increase. A Northern blot
analysis shows that creating the KspI site and inserting the
SL-A sequence in pCMV-RZLUC do not influence the transcription of
bicistronic mRNA (lanes c to e, Fig. 9). We also show that inserting
the SL-A sequence into the APA-FS and
BA mutants of pCMV-R-LUC does
not cause the translation of the downstream ORF (Fig. 5). This finding
excludes the possibility that the SL-A sequence itself plays a role in
translation initiation. Based on the fact that Zta translation probably
does not involve translation reinitiation, we hypothesize that the
intercistronic region may contain a ribosome entry site (internal
initiation) or an acceptor site (ribosome shunting), allowing the
initiation of Zluc translation. If this hypothesis is correct,
inserting a hairpin structure, which prevents ribosome scanning,
downstream from the site should prevent the translation of the
downstream ORF. This investigation finds that inserting the SL-B
sequence, which is known to block ribosome scanning, into the
StyI site in the intercistronic region does prevent the
translation of Zluc (Fig. 5), suggesting that the site may exist
upstream from or near the StyI site.
The sequence complementarity between region I and helix 36 of 18S
rRNA is important for Zluc translation.
Computer analysis
indicates that the intercistronic region may form two large hairpin
structures, SI and SII (Fig. 1B). These structures are unimportant for
the bicistronic translation, since destroying the SI structure (Fig. 6,
5'-85) and the SII structure (Fig. 6, 3'-166) does not affect the
translation. This study also demonstrates that the intercistronic
region is critical in translating the downstream ORF from the
bicistronic mRNA, since replacing the intercistronic region with a
sequence from the BamHI-C fragment of EBV does not cause
translation (Fig. 2). According to deletion analysis, the region
between nucleotides 86 and 165 is especially important (Fig. 6).
Computer analysis also reveals that the region between nucleotides 86 and 125 (region I) in the intercistronic region is partially
complementary to helix 36 of 18S rRNA (from nucleotide 1489 to
nucleotide 1524 of 18S rRNA) (Fig. 8A and B), a region exposed to the
surface of the ribosome and involved in translocation and translation
termination (26, 27, 38, 40, 50, 52). Linker-scanning
analysis also reveals that the level of luciferase translation by the
mutants correlates with the degree of homology between the two
molecules (Fig. 7 and 8A). For instance, the region between nucleotide
106 and nucleotide 115 has the highest degree of homology (Fig. 8A),
and a mutant with a mutation in this region (M106-115) exhibited the
lowest luciferase activity (Fig. 7). Notably, the first 20 nucleotides
of region I are less homologous to 18S rRNA (Fig. 8A), and mutations in
this region (M86-95 and M96-105) do not decrease luciferase activity as
much as does the M106-115 mutation (Fig. 7). Additionally, a point mutation at nucleotide 104 (in the fourth initiation codon) (Fig. 1B
and 8A), creating one mismatch, reduces luciferase translation by 40%
(Fig. 4, 4th). Furthermore, inserting the region I sequence into the
intercistronic region of pCMV-R-LUC(BC) partially restores the
translation, indicating that region I may act as a ribosome entry site
or an acceptor site for the translation of the downstream ORF. This
work also demonstrates that, although region II alone does not support
the translation of luciferase from the bicistronic mRNA (Fig. 8,
BC-RII), without region II, translation of luciferase from the
bicistronic mRNA is inefficient (Fig. 8, BC-RI). These observations
suggest that, instead of providing a site for ribosome binding, region
II may assist the binding of 40S ribosome to region I. Notably, the 18S
rRNA sequence in pCMV-R-LUC(18SC) does not contain a sequence which is
complementary to the sequence of region II. However, pCMV-R-LUC(18SC)
expresses a luciferase activity at the wild-type level (Fig. 8C),
suggesting that, when the intercistronic region contains a sequence
that is already 100% homologous to the helix 36 region of 18S rRNA,
region II may become redundant. This sequence complementarity may
indeed be important since Yueh and Schneider (54) recently
demonstrated that translation by ribosome shunting on the late
adenovirus mRNA and mammalian hsp70 mRNA also involves a
sequence complementarity between the untranslated region of the mRNAs
and sequences in the 3' region of 18S rRNA.
Zluc translation involves either ribosome shunting or internal
entry.
The mechanism translating Zta from the BRLF1-BZLF1
bicistronic mRNA appears complex. Our earlier study demonstrated that
mutations in BRLF1 abolish the translation of Zta from the bicistronic
mRNA. Furthermore, these mutations can be genetically complemented with a functional BRLF1 in cis, indicating that Rta is required
for Zta translation from the bicistronic mRNA (9). Our
current study suggests that translation of Zta from the bicistronic
mRNA may use a shunting mechanism similar to that involved in the
translation of cauliflower mosaic virus 35S RNA, in which case ribosome
shunting requires a virus-encoded translational transactivator
(21, 22). In the case of EBV, Rta may participate in the
ribosome shunting process to assist the ribosomes that translated Rta
in translocating to region I. It is also likely that the region I
sequence may simply serve as an IRES. After interacting with Rta, 40S
ribosomes may bind to this site (internal initiation). Meanwhile,
computer analysis revealed that the sequence of the N-terminal 482 amino acids of Rta is 21% identical and 53% similar to that of eIF-4B (STM protein) of S. cerevisiae (3, 12; data not
shown). As is generally known, eIF-4B may be capable of mediating
complex formation between mRNA and ribosomes via interactions with rRNA (4). eIF-4B is also involved in internal initiation from
IRESs in picornaviruses (43). These findings suggest that
Rta might function as a translation initiation factor to facilitate Zta translation. As is generally known, yeast eIF-4B does not share extensive sequence homology with human eIF-4B. This may explain why
human eIF-4B, which should be abundant in cells, cannot substitute for
Rta in Zta translation (9). Results presented herein not only provide further insight into how Zta protein is translated from
the BRLF1-BZLF1 bicistronic mRNA but also indicate the importance of
transcription of the BRLF1-BZLF1 bicistronic mRNA in activating the EBV
lytic cycle.
 |
ACKNOWLEDGMENTS |
We thank Li-Kwan Chang for her technical assistance.
This work was supported by a medical research grant from the Chang-Gung
Memorial Hospital (CMRP-720III) and by a grant from the National Health
Research Institutes (NHRI-GT-EX89S901L) of the Republic of China.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Molecular
Genetics Laboratory, Department of Microbiology and Immunology,
Chang-Gung University, Kwei-Shan, Taoyuan 333, Taiwan. Phone and fax:
886 3328 0292. E-mail: cgliu{at}mail.cgu.edu.tw.
 |
REFERENCES |
| 1.
|
Abastado, J. P.,
P. F. Miller,
B. M. Jackson, and A. G. Hinnebusch.
1991.
Suppression of ribosomal reinitiation at upstream open reading frames in amino acid-starved cells forms the basis for GCN4 translational control.
Mol. Cell. Biol.
11:486-496[Abstract/Free Full Text].
|
| 2.
|
Adamson, A. L.,
D. Darr,
E. Holley-Guthrie,
R. A. Johnson,
A. Mauser,
J. Swenson, and S. Kenney.
2000.
Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases.
J. Virol.
74:1224-1233[Abstract/Free Full Text].
|
| 3.
|
Altmann, M.,
P. P. Muller,
B. Wittmer,
F. Ruchti,
S. Lanker, and H. Trachsel.
1993.
A Saccharomyces cerevisiae homologue of mammalian translation initiation factor 4B contributes to RNA helicase activity.
EMBO J.
12:3997-4003[Medline].
|
| 4.
|
Altmann, M.,
B. Wittmer,
N. Methot,
N. Sonenberg, and H. Trachsel.
1995.
The Saccharomyces cerevisiae translation initiation factor Tif3 and its mammalian homologue, eIF-4B, have RNA annealing activity.
EMBO J.
14:3820-3827[Medline].
|
| 5.
|
Baer, R.,
A. T. Bankier,
M. D. Biggin,
P. L. Deininger,
P. J. Farrell,
T. J. Gibson,
G. Hatfull,
G. S. Hudson,
S. C. Satchwell, and C. Seguin.
1984.
DNA sequence and expression of the B95-8 Epstein-Barr virus genome.
Nature
310:207-211[CrossRef][Medline].
|
| 6.
|
Bauer, G.,
P. Hofler, and M. Simon.
1982.
Epstein-Barr virus induction by a serum factor. Characterization of the purified factor and the mechanism of its activation.
J. Biol. Chem.
257:11411-11415[Abstract/Free Full Text].
|
| 7.
|
Biggin, M.,
M. Bodescot,
M. Perricaudet, and P. Farrell.
1987.
Epstein-Barr virus gene expression in P3HR1-superinfected Raji cells.
J. Virol.
61:3120-3132[Abstract/Free Full Text].
|
| 8.
|
Chang, L.-K., and S.-T. Liu.
2000.
Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation.
Nucleic Acids Res.
28:3918-3925[Abstract/Free Full Text].
|
| 9.
|
Chang, P. J.,
Y. S. Chang, and S. T. Liu.
1998.
Role of Rta in the translation of bicistronic BZLF1 of Epstein-Barr virus.
J. Virol.
72:5128-5136[Abstract/Free Full Text].
|
| 10.
|
Chenik, M.,
K. Chebli, and D. Blondel.
1995.
Translation initiation at alternate in-frame AUG codons in the rabies virus phosphoprotein mRNA is mediated by a ribosomal leaky scanning mechanism.
J. Virol.
69:707-712[Abstract].
|
| 11.
|
Chevallier-Greco, A.,
H. Gruffat,
E. Manet,
A. Calender, and A. Sergeant.
1989.
The Epstein-Barr virus (EBV) DR enhancer contains two functionally different domains: domain A is constitutive and cell specific, domain B is transactivated by the EBV early protein R.
J. Virol.
63:615-623[Abstract/Free Full Text].
|
| 12.
|
Coppolecchia, R.,
P. Buser,
A. Stotz, and P. Linder.
1993.
A new yeast translation initiation factor suppresses a mutation in the eIF-4A RNA helicase.
EMBO J.
12:4005-4011[Medline].
|
| 13.
|
de Wet, J. R.,
K. V. Wood,
M. DeLuca,
D. R. Helinski, and S. Subramani.
1987.
Firefly luciferase gene: structure and expression in mammalian cells.
Mol. Cell. Biol.
7:725-737[Abstract/Free Full Text].
|
| 14.
|
Faggioni, A.,
C. Zompetta,
S. Grimaldi,
G. Barile,
L. Frati, and J. Lazdins.
1986.
Calcium modulation activates Epstein-Barr virus genome in latently infected cells.
Science
232:1554-1556[Abstract/Free Full Text].
|
| 15.
|
Farrell, P. J.,
D. T. Rowe,
C. M. Rooney, and T. Kouzarides.
1989.
Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos.
EMBO J.
8:127-132[Medline].
|
| 16.
|
Fixman, E. D.,
G. S. Hayward, and S. D. Hayward.
1995.
Replication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays.
J. Virol.
69:2998-3006[Abstract].
|
| 17.
|
Flemington, E., and S. H. Speck.
1990.
Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1.
J. Virol.
64:1227-1232[Abstract/Free Full Text].
|
| 18.
|
Flemington, E. K.,
A. E. Goldfeld, and S. H. Speck.
1991.
Efficient transcription of the Epstein-Barr virus immediate-early BZLF1 and BRLF1 genes requires protein synthesis.
J. Virol.
65:7073-7077[Abstract/Free Full Text].
|
| 19.
|
Furnari, F. B.,
V. Zacny,
E. B. Quinlivan,
S. Kenney, and J. S. Pagano.
1994.
RAZ, an Epstein-Barr virus transdominant repressor that modulates the viral reactivation mechanism.
J. Virol.
68:1827-1836[Abstract/Free Full Text].
|
| 20.
|
Futterer, J.,
K. Gordon,
H. Sanfacon,
J. M. Bonneville, and T. Hohn.
1990.
Positive and negative control of translation by the leader sequence of cauliflower mosaic virus pregenomic 35S RNA.
EMBO J.
9:1697-1707[Medline].
|
| 21.
|
Futterer, J., and T. Hohn.
1991.
Translation of a polycistronic mRNA in the presence of the cauliflower mosaic virus transactivator protein.
EMBO J.
10:3887-3896[Medline].
|
| 22.
|
Futterer, J.,
Z. Kiss-Laszlo, and T. Hohn.
1993.
Nonlinear ribosome migration on cauliflower mosaic virus 35S RNA.
Cell
73:789-802[CrossRef][Medline].
|
| 23.
|
Futterer, J.,
I. Potrykus,
Y. Bao,
L. Li,
T. M. Burns,
R. Hull, and T. Hohn.
1996.
Position-dependent ATT initiation during plant pararetrovirus rice tungro bacilliform virus translation.
J. Virol.
70:2999-3010[Abstract].
|
| 24.
|
Ho, S. N.,
H. D. Hunt,
R. M. Horton,
J. K. Pullen, and L. R. Pease.
1989.
Site-directed mutagenesis by overlap extension using the polymerase chain reaction.
Gene
77:51-59[CrossRef][Medline].
|
| 25.
|
Holley-Guthrie, E. A.,
E. B. Quinlivan,
E. C. Mar, and S. Kenney.
1990.
The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner.
J. Virol.
64:3753-3759[Abstract/Free Full Text].
|
| 26.
|
Holmberg, L., and O. Nygard.
1994.
Interaction sites of ribosome-bound eukaryotic elongation factor 2 in 18S and 28S rRNA.
Biochemistry
33:15159-15167[CrossRef][Medline].
|
| 27.
|
Holmberg, L., and O. Nygard.
1997.
Mapping of nuclease-sensitive sites in native reticulocyte ribosomes an analysis of the accessibility of ribosomal RNA to enzymatic cleavage.
Eur. J. Biochem.
247:160-168[Medline].
|
| 28.
|
Hope, I. A., and K. Struhl.
1985.
GCN4 protein, synthesized in vitro, binds HIS3 regulatory sequences: implications for general control of amino acid biosynthetic genes in yeast.
Cell
43:177-188[CrossRef][Medline].
|
| 29.
|
Kenney, S.,
E. Holley-Guthrie,
E. C. Mar, and M. Smith.
1989.
The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators.
J. Virol.
63:3878-3883[Abstract/Free Full Text].
|
| 30.
|
Kenney, S.,
J. Kamine,
E. Holley-Guthrie,
J. C. Lin,
E. C. Mar, and J. Pagano.
1989.
The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters.
J. Virol.
63:1729-1736[Abstract/Free Full Text].
|
| 31.
|
Kieff, E.
1996.
Epstein-Barr virus and its replication, 3rd ed.
Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 32.
|
Kozak, M.
1989.
Circumstances and mechanisms of inhibition of translation by secondary structure in eucaryotic mRNAs.
Mol. Cell. Biol.
9:5134-5142[Abstract/Free Full Text].
|
| 33.
|
Kozak, M.
1987.
Effects of intercistronic length on the efficiency of reinitiation by eucaryotic ribosomes.
Mol. Cell. Biol.
7:3438-3445[Abstract/Free Full Text].
|
| 34.
|
Kozak, M.
1989.
The scanning model for translation: an update.
J. Cell Biol.
108:229-241[Abstract/Free Full Text].
|
| 35.
|
Luka, J.,
B. Kallin, and G. Klein.
1979.
Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate.
Virology
94:228-231[CrossRef][Medline].
|
| 36.
|
Luukkonen, B. G.,
W. Tan, and S. Schwartz.
1995.
Efficiency of reinitiation of translation on human immunodeficiency virus type 1 mRNAs is determined by the length of the upstream open reading frame and by intercistronic distance.
J. Virol.
69:4086-4094[Abstract].
|
| 37.
|
Manet, E.,
H. Gruffat,
M. C. Trescol-Biemont,
N. Moreno,
P. Chambard,
J. F. Giot, and A. Sergeant.
1989.
Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators.
EMBO J.
8:1819-1826[Medline].
|
| 38.
|
Moazed, D., and H. F. Noller.
1987.
Interaction of antibiotics with functional sites in 16S ribosomal RNA.
Nature
327:389-394[CrossRef][Medline].
|
| 39.
|
Mueller, P. P., and A. G. Hinnebusch.
1986.
Multiple upstream AUG codons mediate translational control of GCN4.
Cell
45:201-207[CrossRef][Medline].
|
| 40.
|
Murgola, E. J.,
K. A. Hijazi,
H. U. Goringer, and A. E. Dahlberg.
1988.
Mutant 16S ribosomal RNA: a codon-specific translational suppressor.
Proc. Natl. Acad. Sci. USA
85:4162-4165[Abstract/Free Full Text].
|
| 41.
|
Oh, S. K., and P. Sarnow.
1993.
Gene regulation: translational initiation by internal ribosome binding.
Curr. Opin. Genet. Dev.
3:295-300[CrossRef][Medline].
|
| 42.
|
Pelletier, J., and N. Sonenberg.
1988.
Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA.
Nature
334:320-325[CrossRef][Medline].
|
| 43.
|
Pestova, T. V.,
C. U. Hellen, and I. N. Shatsky.
1996.
Canonical eukaryotic initiation factors determine initiation of translation by internal ribosomal entry.
Mol. Cell. Biol.
16:6859-6869[Abstract].
|
| 44.
|
Ragoczy, T.,
L. Heston, and G. Miller.
1998.
The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes.
J. Virol.
72:7978-7984[Abstract/Free Full Text].
|
| 45.
|
Rickinson, A. B., and E. Kieff.
1996.
Epstein-Barr virus, 3rd ed.
Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 46.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 47.
|
Sanger, F.,
S. Nicklen, and A. R. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467[Abstract/Free Full Text].
|
| 48.
|
Schepers, A.,
D. Pich, and W. Hammerschmidt.
1993.
A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus.
EMBO J.
12:3921-3929[Medline].
|
| 49.
|
Shimizu, N.,
S. Sakuma,
Y. Ono, and K. Takada.
1989.
Identification of an enhancer-type sequence that is responsive to Z and R trans-activators of Epstein-Barr virus.
Virology
172:655-658[CrossRef][Medline].
|
| 50.
|
Sigmund, C. D.,
M. Ettayebi, and E. A. Morgan.
1984.
Antibiotic resistance mutations in 16S and 23S ribosomal RNA genes of Escherichia coli.
Nucleic Acids Res.
12:4653-4663[Abstract/Free Full Text].
|
| 51.
|
Takada, K., and Y. Ono.
1989.
Synchronous and sequential activation of latently infected Epstein-Barr virus genomes.
J. Virol.
63:445-449[Abstract/Free Full Text].
|
| 52.
|
Tate, W.,
B. Greuer, and R. Brimacombe.
1990.
Codon recognition in polypeptide chain termination: site directed crosslinking of termination codon to Escherichia coli release factor 2.
Nucleic Acids Res.
18:6537-6544[Abstract/Free Full Text].
|
| 53.
|
Tsukiyama-Kohara, K.,
N. Iizuka,
M. Kohara, and A. Nomoto.
1992.
Internal ribosome entry site within hepatitis C virus RNA.
J. Virol.
66:1476-1483[Abstract/Free Full Text].
|
| 54.
|
Yueh, A., and R. J. Schneider.
2000.
Translation by ribosome shunting on adenovirus and hsp70 mRNAs facilitated by complementarity to 18S rRNA.
Genes Dev.
14:414-421[Abstract/Free Full Text].
|
| 55.
|
zur Hausen, H.,
F. J. O'Neill,
U. K. Freese, and E. Hecker.
1978.
Persisting oncogenic herpes-virus induced by tumor promoter TPA.
Nature
272:373-375[CrossRef][Medline].
|
Journal of Virology, February 2001, p. 1142-1151, Vol. 75, No. 3
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.3.1142-1151.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.